date 01.12.2008 drug regulatory process, the supporting information systems, and the escher- project...
Post on 17-Jan-2016
213 Views
Preview:
TRANSCRIPT
Date 01.12.2008
Drug regulatory process, the supporting information systems, and the Escher-projectTommi TervonenFaculty of Economics and BusinessUniversity of Groningent.p.tervonen@rug.nl
Date 01.12.2008
What is drug discovery and drug development?
Ambit biosciences, commercial compound DBs (ambitbio.com)
Example drug development costs of Trimeris Inc. (thebody.com)
Date 01.12.2008
>What are Drug Information Systems (DISs)?>What are they being used for?>Who uses them?>What could they be used for?
Discovery
Development Launch
Pre-clinical trials
Clinical trials
Phase I Phase II Phase III
Marketing
Phase IV clinical trials
Drug lifecycle
Date 01.12.2008
> DIS classes Compound DBs Pre/clinical trial DBs Summary of Product Characteristics (SmPC) DBs Adverse Drug Reaction (ADR) DBs CPOEs
Discovery
Development La
un
ch
Pre-clinical trials
Clinical trials
Phase I Phase II Phase III
Pre/clinical trial DBs
Compound DBs
Marketing
Phase IV clinical trials
ADR DBs
SmPC DBs
CPOEs
Tim
e
Date 01.12.2008
DIS Data Organization
Class Name
Type (Structural/Trial/Reg
ulative/Patient) Details
Qu
antitative
(Yes/N
o)
Ag
greg
ated/R
aw
Name
No
n-p
rofit (Y
es/No
)
Compound Cambridge structural database
S Molecule crystal structures Y R CCDC NCompound NCI 3D database S Molecular 3d structures Y R NCI Y
CT clinicaltrials.gov T Only CT settings and objectives N A NIH / FDA YCT Janus T, R Not functional yet Y A, R FDA YCT EudraCT T No public functionality* N A EMEA YCT Cochrane T CT Meta-analyses Y A Cochrane YCT clinicalstudyresults.org T Detailed clinical study results N A PhRMA N
CT / SmPC NCI Drug Dictionary/thesaurus
T, RSmPC and clinical trials for cancer drugs N A NCI Y
SmPC Drug Information Online RSmPC, drug interactions, condition medication, pill labeling N A
Micromedex, Cerner Multum, Wolter Kluwer,
and others N
SmPC RxList RSmPC, drug interactions, condition medication, pill labeling N A RxList, Inc. N
SmPC Lung Association of Saskatchewan lung disease drug repository
RSmPCs for drugs with indication in lung diseases N A
Lung Association of Saskatchewan Y
SmPC Drug Digest RSmPC, drug interactions, pill labeling N N
SmPC DailyMed R Detailed SmPC N A NLM YSmPC EMEA EPAR R EPAR, incl. detailed SmPC Y A EMEA YADR MedEffect R Superficial ADR N A Health Canada YADR FDA ADR R ADR quarterly reports N A FDA YADR EMEA ADR R No public functionality* N A EMEA Y
CPOE Various R, P SmPC through internal SmPC DB N A Various N
Date 01.12.2008
> The drug regulatory process Aims to make sure, that the drugs entering market are both safe and efficient Is laborious and slow Has relatively poor dissemination of results Doesn’t have transparent decision making Has recently all participating parties (drug industry, academia, and regulatory authorities) concerned about reforming
the process
> The main reason forreforming the regulatoryprocess is to limitthe linear growthof costs,but…
Benefit-risk assessment
Data and evidence
Regulatory Logic
Date 01.12.2008
>The current DISs don’t store regulatory information of sufficient precision; only aggregated information is available
>Systematic, quantitative analysis is not possible without suitable quantitative information. Current Benefit-Risk analysis is qualitative!
Discovery
Development Launch
Pre-clinical trials
Clinical trials
Phase I Phase II Phase III
Pre/clinical trial DBs
Compound DBs
Marketing
Phase IV clinical trials
ADR DBs
SmPC DBs
CPOEs
Tim
e
Date 01.12.2008
>Dose-response curve-fitting with various A-II antagonists
Dose (mg/d)
-12
-10
-8
-6
-4
-2
0
0 100 200 300
Tro
ugh D
BP
(m
m H
g)
Dose (mg/d)
-12
-10
-8
-6
-4
-2
0
0 50 100 150 200
Tro
ugh D
BP
(m
m H
g)
Similar compounds, partially different indications, totally different clinical data!
Date 01.12.2008
Escher-projectWorkpackages 3.1 and 3.2
Date 01.12.2008
>ESCHER Is a TI-Pharma project with an objective to
“demonstrate, that another way is possible” Incorporates 3 universities (+medical centers), 4
PostDocs, 17 PhD students, 4 drug development companies, and x external personnel
WP 3.1: develop a new framework for drug benefit-risk assessment
WP 3.2: build a drug information system that allows quantitative comparisons
>Benefit-risk analysis of WP 3.1 requires data from the DIS of WP 3.2
Date 01.12.2008
>Escher 3.1 How can we measure benefits and risks?- Rank drugs and placebo for the same indication- Multiple criteria
Inherent value judgements- But what about clashing / missing preference
information? Quantitative data available- But data is uncertain!- Should it be used “as is”?
Multi-Criteria Decision Analysis (MCDA)
Date 01.12.2008
> Stochastic Multicriteria Acceptability Analysis (SMAA) Allows MCDA with
imprecise criteria measurements and missing/incomplete preference information
Criteria measurements can be defined through joint probability distributions -> RCT data can be used +- directly
Date 01.12.2008
> SMAA central weights Central weights are “typical” preferences that
favour different alternatives Although drug A might not have “better” benefit-
risk ratio than drug B with all preferences, some preferences usually support A as well
Elevator planning with SMAA
Date 01.12.2008
>Rank acceptability indices describe stability of ranking, and can be used in risk management
b1
b3
b5
b7
b9
BE
N
CA
S
DA
K
TA
N
AG
A
RA
B
OU
J
MA
R
FE
Z0
10
20
30
40
50
60
70
80
Acceptability
Rank
Alternative
Rank acceptability indices
BEN
CAS
DAK
TAN
AGA
RAB
OUJ
MAR
FEZ
Choosing a location for a new cargo airport in Morocco with SMAA
Date 01.12.2008
>Escher 3.2 Supports various other workpackages by
building an information system that allows quantitative analyses
Web-based drug repository (Java, Spring) Agile development Enables various new
research topics
Date 01.12.2008W
hy A
gile
?
Date 01.12.2008
>How to model relevant data (SmPC)?
5.1 Pharmacodynamic propertiesPharmacotherapeutic group: Drugs used in erectile dysfunction. ATC Code: G04B E03…Studies in vitro have shown that sildenafil is selective for PDE5, which is involved in the erectionprocess. Its effect is more potent on PDE5 than on other known phosphodiesterases. There is a 10-foldselectivity over PDE6 which is involved in the phototransduction pathway in the retina. At maximumrecommended doses, there is an 80-fold selectivity over PDE1, and over 700-fold over PDE2, 3, 4, 7,8, 9, 10 and 11. In particular, sildenafil has greater than 4,000-fold selectivity for PDE5 over PDE3,the cAMP-specific phosphodiesterase isoform involved in the control of cardiac contractility.…
5.1 Pharmacodynamic properties Pharmacotherapeutic group: {group [lowest available level]}, ATC code: {code} [For products approved under “conditional approval”, include the following statement:] <This medicinal product has been authorised under a so-called “conditional approval” scheme. This means that further evidence on this medicinal product is awaited. The European Medicines Agency (EMEA) will review new information on the product every year and this SPC will be updated as necessary.> [For products approved under “exceptional circumstances”, include the following statement:] <This medicinal product has been authorised under “Exceptional Circumstances”. This means that due to <the rarity of the disease> <for scientific reasons> <for ethical reasons> it has not been possible to obtain complete information on this medicinal product. The European Medicines Agency (EMEA) will review any new information which may become available every year and this SPC will be updated as necessary.>
Template Viagra SmPC
Date 01.12.2008
>US Food and Drug Administration (FDA) is working to build a DIS (Janus) incorporating “raw” data
>The European Medicines Agency (EMEA) doesn’t see aggregated data as a problem
>Cause? FDA is multi-disciplinary, EMEA consists of medical doctors
Date 01.12.2008
>Conclusions Drug regulatory process is in need of reform Current drug information systems cannot
support the future needs, because they don’t store the data in an appropriate format
Escher-project tries to show, that a different “way of doing things” is possible
Department of B&IS participates in the project through Bert, Tommi, Vahid, Douwe (starting 1d/w@Jan), and 1 more PhD-student (starting@Apr)
Date 01.12.2008
>Thank you!>Q?>Future publications:
T. Tervonen, V. Oskuee, E.O. de Brock, P.A. de Graef, H.L. Hillege (2008). Current status and future perspectives in Drug Information Systems (manuscript)
T. Tervonen, D. Postmus, H.L. Hillege (2009) Multi-criteria decision analysis in drug benefit-risk analysis. Invited presentation, 23rd European Conference on Operational Research, Bonn, Germany. July 5-8, 2009
>/dev/null
top related